Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society

Breast Cancer

Volumn 5, Issue 3, 1998, Pages 243-249

  Umemura, Shinobu ^a   Komaki, Kansei ^b   Noguchi, Shinzaburo ^c   Shiba, Eiichi ^c   Toi, Masakazu ^d   Kimijima, Izo ^e   Itoh, Hitoshi ^a   Osamura, Yoshiyuki R ^a  

^a TOKAI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Node negative breast cancer; Prognostic factor

Indexed keywords

EID: 0348017135     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966703     Document Type: Article

References (64)

1. Noguchi S, Aihara T, Nakamori S, et al: Detection of micrometastasis of breast carcinoma in axillary lymph nodes by means of reverse transcriptasepolymerase chain reaction. Cancer 74:1595-1600, 1994. (Pubitemid 24302980)
2. Uchida K, Matsuura Y, Hori M, et al: Recurrent breast cancer with no lymph node metastasis at the primary operation. Jap J Cancer Clin 25:1466-1469, 1979.
3. Koyama H, Asaishi K, Yoshimoto M, et al: Recurrence of node-negative breast cancer. Jpn J Breast Cancer 4:69-75, 1989.
4. Wenger CR, Beardslee S, Owens MA, et al: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20, 1993. (Pubitemid 24018192)
5. Gasparini G, Bevilacqua P, Boracchi P, et al: Prognostic value of p53 expression in early-stage breast carcinoma compared with tumour angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin D, DNA ploidy, parameters of cell kinetics and conventional features. Int J Oncol 4:155-162, 1994. (Pubitemid 24012576)
6. Sasa M, Kondo K, Komaki K, et al: p53 alteration corelates with negative ER, negative PgR, and high histologic grade in breast cancer. J Surg Oncol 56:46-50, 1994. (Pubitemid 24149877)
7. Roux Dosseto M, Romain S, Dussault N, et al: c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 28 A: 1600-1604, 1992.
8. Toi M, Taniguchi T, Yamamoto Y, et al: Clinical significance of the determination of angiogenic factors. Eur J Cancer 32 A: 2513-2519, 1996.
9. Japan Mammary Cancer Society: General rule for clinical and histological record of mammary cancer. Jpn J Surg 5:118-131, 1975.
10. Toi M, Hoshina S, Taniguchi T, et al: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 64:79-82, 1995.
11. Kimijima I, Watanabe T, Abe R: Prognostic value of nuclear grading assessed by image cytometry for node negative breast cancer patients. Anticancer Res 16:3494-3954, 1996.
12. Remmele W, Muhlfait V, Keul HG: Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies; Comparative studies on frozen and paraffin sections. Virchows Arch 426:435-439, 1995.
13. Victorzon M, Roberts PJ, Haglund C, et al: Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology 53:182-191, 1996. (Pubitemid 26131940)
14. Chowdhury GM, Kojima K, Kanayama H, et al: The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer 78:827-833, 1996. (Pubitemid 26268614)
15. Harpole DH Jr, Richards WG, Herndon JE 2nd, et al: Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470-1476, 1996. (Pubitemid 26150240)
16. Querzoli P, Albonico G, Ferretti S, et al: MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol 49:926-930, 1996. (Pubitemid 26403164)
17. Molino A, Micciolo R, Turazza M, et al: Ki-67 immunostaining in 322 primary breast cancers; Associations with clinical and pathological variables and prognosis. Int J Cancer 74:433-437, 1997. (Pubitemid 27400164)
18. Veronese SM, Maisano C, Scibilia J: Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 15:2717-2722, 1995. (Pubitemid 26095087)
19. Railo M, Nordling S, von Boguslawsky K, et al: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68:579-583, 1993. (Pubitemid 23258465)
20. Veronese SM, Gambacorta M, Gottardi O, et al: Proliferation index as a prognostic marker in breast cancer. Cancer 71:3926-3931, 1993. (Pubitemid 23172971)
21. Railo M, Lundin J, Haglund C, et al: Ki-67, p53, Erreceptors, ploidy and S-phase as prognostic factors in Tl node negative breast cancer. Acta Oncol 36:369-374, 1997. (Pubitemid 27298555)
22. Pierga JY, Leroyer A, Viehl P, et al: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37:57-64, 1996. (Pubitemid 26028246)
23. Jensen V, Ladekarl M, Holm Nielsen P, et al: The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node negative breast cancer. J Pathol 176:343-352, 1995.
24. Kawamoto H, Koizumi H, Uchikoshi T: Expression of the G2-M checkpoint regulators cyclin Bl and cdc2 in nonmalignant and malignant human breast lesions; Immunocytochemical and quantitative image analyses. Am J Pathol 150:15-23, 1997. (Pubitemid 27027091)
25. Dees C, Garrett S, Henley D, et al: Effects of 60-Hz fields, estradiol and xenoestrogens on human breast cancer cells. Radiat Res 146:444-452, 1996. (Pubitemid 26332776)
26. Musgrove EA, Hamilton JA, Lee CS, et al: Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587, 1993. (Pubitemid 23157295)
27. Said TK, Medina D: Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development. Carcinogenesis 16:823-830, 1995.
28. Ohta T, Fukuda M, Arima K, et al: Analysis of cdc2 and cycin Dl expression in breast cancer immunoblotting. Breast Cancer 4:17-24, 1997.
29. Theissig F, Baak JP, Schuurmans L, et al: 'Blind' multicenter evaluation of the prognostic value of DNA image cytometric and morphometric features in invasive breast cancer. Anal Cell Pathol 10:85-99, 1996. (Pubitemid 26092453)
30. Ladekarl M, Jensen V: Quantitative histopathology in lymph node-negative breast cancer; Prognostic significance of mitotic counts. Virchows Arch 427:265-270, 1995.
31. Aaltomaa S, Lipponen P, Eskelinen M, et al: Mitotic indexes as prognostic predictors in female breast cancer. J Cancer Res Clin Oncol 118:75-81, 1992.
32. Witzig TE, Ingle JN, Cha SS, et al: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer 74:1752-1761, 1994. (Pubitemid 24301830)
33. McGrath PC, Holley DT, Hamby LS, et al: Proliferation-associated nucleolar antigen P120; A prognostic marker in node-negative breast cancer. Surgery 116:616-620, 1994.
34. Siitonen SM, Kallioniemi OP, Helin HJ, et al: Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. Hum Pathol 24:1348-1353, 1993. (Pubitemid 24033738)
35. Stierer M, Rosen H, Weber R: Nuclear pleomorphism, a strong prognostic factor in axillary node-negative small invasive breast cancer. Breast Cancer Res Treat 20:109-116, 1992.
36. Schonborn I, Zschiesche W, Minguillon C, et al: Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer. J Cancer Res Clin Oncol 121:115-122, 1995.
37. Aaltomaa S, Lipponen P, Syrjanen K: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res 13:533-538, 1993. (Pubitemid 23196799)
38. Nielsen NH, Arnerlov C, Emdin SO, et al: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74:874-880, 1996. (Pubitemid 26319319)
39. Picker LJ, Nakache M, Butcher EC: Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on divere cell types. J Cell Biol 109:927-937, 1989. (Pubitemid 19197049)
40. Jalkanen S, Bargatze RF, De Los Toyos J, et al: A lymphoid cell surface protein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 16:1195-1202, 1986. (Pubitemid 17171524)
41. Herrlich P, Pals S, Ponta H: CD44 in colon cancer. Eur J Cancer 31:1110-1112, 1995.
42. Kainz C, Kohlberger P, Tempter C, et al: Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer 31:1706-1709, 1995.
43. Dall P, Heider KH, Hekele A, et al: Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 54:3337-3341, 1994. (Pubitemid 24225943)
44. Kan M, Aki M, Akiyama K, et al: High-level expression of the CD44 variant sharing exon v10 in renal cancer. Jpn J Cancer Res 86:847-853, 1995.
45. Martin S, Jansen F, Bokelmann J, et al: Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer 74:443-445, 1997. (Pubitemid 27400166)
46. Guriec N, Marcellin L, Gairard B, et al: CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 14:434-439, 1996. (Pubitemid 26365120)
47. Kaufmann M, Heider KH, Sinn HP, et al: CD44 variant exon epitopes in primary breast cancer and length of survival [see comments]. Lancet 345 (8950):615-619, 1995.
48. Guriec N, Marcellin L, Gairard B, et al: CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 14:434-439, 1996. (Pubitemid 26365120)
49. Friedrichs K, Franke F, Lisboa BW, et al: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55:5424-5433, 1995.
50. Kallioniemi OR, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991.
51. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991. (Pubitemid 21923993)
52. Pietilainen T, Lipponen P, Aaltomaa S, et al: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177:225-232, 1995.
53. Gohring UJ, Scharl A, Heckel C, et al: P53 protein in 204 patients with primary breast carcinoma; Immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet 256:139-146, 1995.
54. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in nodenegative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992.
55. Van Hoef ME, Knox WF, Dhesi SS, et al: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29 A: 1141-1145, 1993. (Pubitemid 23156639)
56. Shiba E, Lindon JN, Hushiner L, et al: Antibodydetectable changes in fibrinogen absorption affecting platelet activation on polymer surfaces. Am J Physiol 260:965-975, 1991.
57. Janicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993. (Pubitemid 23062819)
58. Isola J, Weitz S, Visakorpi T, et al: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary nodenegative breast cancer. J Clin Oncol 11:36-43, 1993. (Pubitemid 23059972)
59. Ravdin PM, Tandon AK, Allred DC, et al: Cathepsin D by western blotting and immunohistochemistry; Failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12:467-474, 1994.
60. Lauria R, Perrone F, Carlomagno C, et al: The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 76:1772-1778, 1995.
61. Gasparini G, Meli S, Panizzoni GA, et al: Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Treat 20:195-204, 1992.
62. Gasparini G, Barbareschi M, Boracchi P, et al: 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in nodenegative breast cancer. Int J Cancer 60:604-610, 1995.
63. van Slooten HJ, Clahsen PC, van Dierendonck JH, et al: Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74:78-85, 1996. (Pubitemid 26231982)
64. Sheen Chen SM, Chou FF, Eng HL, et al: An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 116:510-515, 1994.